Please check your internet connection and try again.
# Flupentixol and Melitracen
## Overview
Flupentixol is a thioxanthene antipsychotic, and melitracen is a tricyclic antidepressant. This combination is used for the treatment of anxiety and depressive disorders.
## Primary Indications
Anxiety and depressive disorders, particularly when accompanied by symptoms such as apathy, lack of initiative, and fatigue.
## Adult Dosing
* **Starting Dose:** Typically 1 tablet (equivalent to 1 mg flupentixol and 25 mg melitracen) twice daily (morning and noon).
* **Maintenance Dose:** May be increased to 2 tablets three times daily.
* **Maximum Dose:** Not explicitly defined in standard guidelines, but individual doses of flupentixol can go up to 6 mg daily and melitracen up to 75 mg daily, implying a total daily dose of up to 6 tablets could be considered based on patient response and tolerability. Dosing should be individualized.
## Pediatric Dosing
Safety and efficacy in pediatric patients have not been established. Use is generally not recommended.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Dose reduction may be necessary, guided by clinical response and tolerability.
* **Renal Impairment:** Use with caution. Dose adjustment may be considered, though specific guidelines are lacking.
* **Elderly:** Start with lower doses and titrate slowly due to potential increased sensitivity.
## Contraindications
* Hypersensitivity to flupentixol, melitracen, or any excipients.
* Acute excitement, agitation, or overactivity.
* Central nervous system depression.
* Circulatory collapse.
* Glaucoma (narrow-angle).
* Untreated narrow-angle glaucoma.
* Hyperthyroidism.
* Recent myocardial infarction.
* Concomitant use with MAOIs or within 14 days of discontinuing MAOIs.
## Adverse Effects
**Common:** Dry mouth, constipation, blurred vision, urinary retention, drowsiness, dizziness, headache, fatigue, tremor, insomnia, agitation, increased sweating.
**Serious:** Extrapyramidal symptoms (akathisia, dystonia, parkinsonism), tardive dyskinesia (especially with long-term use), neuroleptic malignant syndrome, cardiac arrhythmias, orthostatic hypotension, syncope, increased risk of suicidal thoughts and behavior (particularly in children and young adults), anticholinergic effects, seizures.
## Key Drug Interactions
* **MAOIs:** Increased risk of hypertensive crisis and serotonin syndrome. Avoid concurrent use and allow a 14-day washout period.
* **CNS Depressants (alcohol, barbiturates, benzodiazepines):** Additive sedative effects.
* **Anticholinergic Agents:** Potentiated anticholinergic effects.
* **Guanethidine/Clonidine:** Reduced hypotensive effect.
* **CYP2D6 Inhibitors (e.g., fluoxetine, paroxetine, quinidine):** May increase flupentixol and melitracen plasma concentrations, potentially increasing adverse effects.
* **QTc Prolonging Agents:** Increased risk of QT interval prolongation and cardiac arrhythmias.
## Monitoring
* **Mental Status:** Assess for improvement in depressive and anxiety symptoms, as well as for any signs of worsening mental state, agitation, or suicidal ideation.
* **Neurological Exam:** Monitor for extrapyramidal symptoms and tardive dyskinesia.
* **Cardiovascular Status:** Monitor blood pressure (supine and standing), heart rate, and ECG if clinically indicated, especially in patients with pre-existing cardiac conditions or those at risk for arrhythmias.
* **Anticholinergic Effects:** Monitor for dry mouth, constipation, urinary retention, and blurred vision.
* **Laboratory Tests:** Baseline and periodic liver function tests may be considered.
## Clinical Pearls
* This combination medication should be initiated at a low dose and titrated slowly, especially in the elderly or those with cardiac disease.
* Patients should be advised to avoid alcohol due to additive CNS depressant effects.
* Inform patients about the risk of drowsiness and advise caution when driving or operating machinery.
* Discontinuation should be gradual to avoid withdrawal symptoms.
* The risk of suicidal thoughts and behavior, particularly at the beginning of treatment or during dose adjustments, requires careful monitoring.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and local protocols for complete and up-to-date guidance. Verify all drug information before use.
